Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Eligibility Criteria

• * Patients must weigh at least 10 kilograms at the time of the study enrollment.
• * Diagnosis
• * Aggressive NK cell leukemia (ICD-O code 9948/3)
• * Extranodal NK/T-cell lymphoma, nasal type (ICD-O code 9719/3) COHORT 2
• * Enteropathy-associated T-cell lymphoma (ICD-O code 9717/3)
• * Hepatosplenic T-cell lymphoma (ICD-O code 9716/3)
• * Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702/3)
• * Angioimmunoblastic T-cell lymphoma (ICD-O code 9705/3)
• * Other mature T- and NK-cell neoplasm histologies will considered after case-by-case discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have stage III or IV disease (See Appendix III for Staging).
• * Organ Function Requirements
• * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.
• * ALT (SGPT) \< 3 x ULN for age.
• * Shortening fraction of ≥ 27% by echocardiogram, or
• * Ejection fraction of ≥ 50% by radionuclide angiogram.
• * Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)
• * Patients with active CNS disease.
• * Patients with stage I or stage II disease (See Appendix III for Staging).
• * Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of NHL.
• * Previous steroid treatment and/or radiation treatment are not allowed unless they are used for emergency management. Patients who have received emergency irradiation and/or steroid therapy will be eligible only if started on protocol therapy not more than one week from the start of radiotherapy or steroids.
• * Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.
• * Lactating females, unless they have agreed not to breastfeed their infants.
• * Patients with Down syndrome.
• * Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2 ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices (See Appendix V). The topical use of these medications (if applicable) is allowed.
• * Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment (See Appendix V). The topical use of these medications (if applicable) is allowed.
• * Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See Appendix V).